Diagnosis and Management of PBC
|
|
- Jeffrey Copeland
- 6 years ago
- Views:
Transcription
1 Diagnosis and Management of PBC Cynthia Levy, MD, FAASLD University of Miami Miller School of Medicine Miami, Florida 1
2 Primary Biliary Cholangitis (PBC) Chronic cholestatic liver disease Autoimmune in nature Inflammation and destruction of small interlobular bile ducts Affects predominantly middle-aged females Rising incidence and prevalence Carey E, et al. Lancet
3 PBC Diagnosis Unexplained Elevation of ALP 1.5x ULN Positive antimitochondrial antibody Non-suppurative destructive cholangitis on histology Two out of these 3 criteria are required for the diagnosis of PBC
4 Variant Syndromes AMA-negative PBC 50% will have antinuclear antibodies (ANA) PBC-specific ANA anti gp210, anti sp100 Same clinical presentation Overlap syndrome with autoimmune hepatitis Consider when ALP: transaminase ratio <1.5, IgG is elevated and smooth muscle antibodies are present with titer >1:80 Premature Ductopenic Variant 5-10% Very rapid onset of ductopenia, severe icteric cholestasis and fast progression towards cirrhosis
5 Clinical Features Vary Greatly Between Patients o Fatigue 1,2 o Pruritus 1,2 o Concurrent autoimmune diseases 1,2 o Reduced bone density 1,2 o Hypercholesterolemia 1,2 o Xanthoma and Xanthelasma 2,3 PBC can range from asymptomatic and slowly progressive to symptomatic and rapidly evolving Selmi C, et al. Lancet. 2011;377(9777): ; 2. Carey EJ, et al. Lancet. 2015;386(10003): ; 3. Lindor KD, et al. Hepatology. 2009;50(1):
6 First Line Therapy: Ursodeoxycholic Acid o Orally administered, naturally occurring, hydrophilic secondary bile acid o Dose: mg/kg/day o Improvement in liver tests may be seen within a few weeks and 90% of the improvement usually occurs within 6-9 months Lindor K, et al. Hepatology. 2009;50:
7 Therapeutic Effects UDCA Improves TB, ALP, GGT, AST and ALT Improves survival free of liver transplantation Improves cholesterol, IgM UDCA mg/kg/day Delays development of esophageal varices Delays histological progression Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; IgM, immunoglobulin M; TB, total bilirubin; UDCA, ursodeoxycholic acid. Levy C and Lindor KD. In: Zakim and Boyer's Hepatology: A Textbook of Liver Disease. Elsevier Inc;2011: Graphic courtesy of Dr. Cynthia Levy.
8 Combined Effect of TB and ALP on Transplant-Free Survival Transplant-Free Survival (%) a-b: P.001 c-d: P.001 ALP and TB at 1 Year Follow-up Time (Years) a b c d a b c d Normal bilirubin and ALP 2.0 x ULN Normal bilirubin and ALP > 2.0 x ULN Abnormal bilirubin and ALP 2.0 x ULN Abnormal bilirubin and ALP > 2.0 x ULN Lammers, et al. Gastroenterology. 2014; 147:
9 Hazard Ratio for LT/Death According to ALP A Hazard Ratio for Liver Transplantation or Death At Baseline* Hazard Ratio for Liver Transplantation or Death At One Year Follow-up* Thresholds (xuln) for Alkaline 5 Phosphatase Values Thresholds (xuln) for Alkaline Phosphatase Values *3710/4635 patients were included for this analysis Lammers, et al. Gastro
10 New Targets for Treatment of Cholestatic Diseases PPAR + MDR3 Trauner M. Hepatology
11 OCA in Patients with PBC: POISE Study Design Placebo (n=73) Screening OCA 5 mg OCA 10 mg (n=73) Titrate to OCA 10 mg (n=33) Remain at OCA 5 mg (n=36) OCA 5 mg OCA 5-10 mg dose adjustment option Months in Open-Label Phase 0 W2 M3 M6 M9 M12 Modified from Nevens F, et al. N Engl J Med. 2016;375:
12 Primary Endpoint in the Double-Blind and Open-Label Extension Phases Placebo Obeticholic acid, 5 10 mg Obeticholic acid, 10 mg 100 Double-Blind Phase Open-Label Phase Patients with Response (%) Month in Double-Blind Phase Month in Open-Label Phase No. of Patients Placebo Obeticholic acid, 5 10 mg Obeticholic acid, 0 mg Nevens F, et al. N Engl J Med. 2016;375:
13 Other Effects of OCA During POISE Trial Significant drop in ALP, AST, ALT, GGT, TB Significant reduction in inflammatory markers Reduction in HDL-cholesterol (20% in 10mg/day, 9% in 5-10 mg/day) No change in liver stiffness scores (50% had LS measured) Significant reduction in serum bile acid levels and increase in FGF 19 levels Main side effect: Pruritus è mitigated by starting at 5 mg/day and only titrating up IF well tolerated Nevens F, et al. NEJM
14 Obeticholic Acid Is Approved: o In combination with UDCA for patients with PBC who have been treated with UDCA for > 1 year and have incomplete response o As monotherapy for patients with PBC who are intolerant to UDCA Improvement in survival free of liver transplantation has not yet been demonstrated. Conditional approval granted
15 Cumulative Incidence of Advanced Stages of PBC Cumulative Incidences 20% 15% 10% 5% 0% 20% A. Decompensated Cirrhosis UDCA OCA plus UDCA Year C. Liver Transplants Cumulative Incidences 20% 15% 10% 5% 0% 20% B. Hepatocellular Carcinoma UDCA OCA plus UDCA Year D. Liver-Related Deaths In patients with inadequate response to UDCA, OCA decreased 15-yr cumulative incidences of: Decompensated cirrhosis from 12.2% to 4.5% HCC from 9.1% to 4% Cumulative Incidences 15% 10% 5% 0% UDCA OCA plus UDCA Year Cumulative Incidences 15% 10% 5% 0% UDCA OCA plus UDCA Year OLT from 4.5% to 1.2% Liver-related deaths from 16.2% to 5.7% Samur S, et al. Hepatology
16 Cost-Effectiveness Study of OCA in PBC o Treating 10,000 patients would prevent: 770 cases of decompensated cirrhosis,510 cases of HCC, 330 OLTs and 1050 liver-related deaths o Lifetime treatment cost of PBC increased from $63,100 to $902,200 (1,330%) with addition of OCA to UDCA o ICER: $473,400/QALY è NOT cost-effective o Recommended price reduction: 73% Samur S, et al. Hepatology
17 WHO SHOULD RECEIVE ADJUVANT THERAPY? WHO IS AT RISK FOR PROGRESSION?
18 PBC - Risk Stratification Pre-Treatment After 1 year of treatment with UDCA Staging: Transient elastography, histology, enhanced liver fibrosis score Age, gender, ethnicity Anti gp 210, anti-centromere Variant syndromes Response to UDCA ALP, TB Mathematical models: Globe PBC, UK PBC Levy C. Hepatology
19 Value of Liver Stiffness in PBC A Survival Without Adverse Outcome Survival According to Baseline LSM 9.6 kpa >9.6 kpa Total Follow-up (Years) B Survival Without Adverse Outcome Survival According to LSM/ t 2.1 kpa/yr >2.1 kpa/yr Extended Follow-up (Years) -LS > 9.6 at baseline associated with 5x increase in risk of adverse outcomes -LS increase >2.1 kpa/year associated with 8x increase in risk of adverse outcomes Corpechot, et al. Hepatology
20 Novel Therapies Under Evaluation for PBC Compound NCT Mechanism of Action Status Bezafibrate Fenofibrate NCT NCT Pan PPAR agonist PPAR alpha agonist Phase 3, Europe has results Phase 2, China NGM 282 NCT FGF 19 analog Phase 2, has results LJN452 NCT FXR agonist Phase 2, recruiting MBX-8025 NCT PPAR delta agonist Phase 2, recruiting FFP104 NCT CD40 Inhibitor Phase 1/2 - Europe Abatacept NCT Inhibits T cell activation Phase 4, ongoing LUM001 NCT ASBT inhibitor Phase 2, complete; primary endpoint: itching GS9674 NCT FXR agonist Phase 2, recruiting GSK 672 NCT IBAT inhibitor Phase 2, recruiting; primary endpoint: itching Genfit PPAR delta agonist Phase 2, not yet recruiting
21 Bezafibrate+UDCA vs. Placebo+UDCA o 100 patients with incomplete response to UDCA o Randomized to BZF 400 mg/day or placebo, for 2 years o Primary endpoint* at 2 years: 30% BZF vs. 0% Placebo o Itch score, LSM and ELF all improved in BZF group 67% 70% 60% 50% 40% 30% 20% 10% 0% 0% normalization ALP BZF Placebo Corpechot C, et al. LB-4195, EASL
22 Summary: Updated Management Strategy Imaging & Labs Pruritus Assess symptoms Fatigue Baseline Evaluation Staging* Sicca Syndrome New Diagnosis Initiate PBC-specific therapy DEXA UDCA mg/kg/day Clinical evaluation Cirrhosis? MRS > 4.1? Thrombocytopenia EGD; HCC surveillance Long-term monitoring Biochemistries Risk stratification after 1 year of therapy Evaluate need for adjuvant therapy Transient elastography Approved: Ocaliva Off label: Fibrates, budesonide
Program Disclosure. This activity is supported by an educational grant from Intercept Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership
More informationNew insights in pathogenesis and therapy of primary biliary cholangitis. Keith D. Lindor Dean Professor of Medicine
New insights in pathogenesis and therapy of primary biliary cholangitis Keith D. Lindor Dean Professor of Medicine OUTLINE PBC Epidemiology Diagnosis Treatment Incidence of PBC and PSC Trends Boonstra
More informationOcaliva (obeticholic acid tablets)
Ocaliva (obeticholic acid tablets) Policy Number: 5.01.619 Last Review: 11/2018 Origination: 11/2016 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ocaliva (obeticholic acid) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ocaliva (obeticholic acid) Prime Therapeutics will review Prior Authorization
More informationPrimary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS
Primary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS Nikolaos T. Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD Associate Professor and Chief, Division of Gastroenterology and Hepatology
More informationObeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks Draft Background and Scope Background: April 21, 2016 Primary biliary cholangitis
More informationPBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
More informationPBC treatment: the present and future. Maggie Bassendine Professor of Hepatology
PBC treatment: the present and future Maggie Bassendine Professor of Hepatology Primary biliary cirrhosis 20-25yrs OLT/ Death Symptoms: Fatigue, itching, jaundice Autoimmune disease: Focal small bile duct
More informationRisk stratification in PBC
Risk stratification in PBC Christophe Corpechot Reference Center for Inflammatory Biliary Diseases Saint-Antoine hospital, Paris, France What is currently known (background) PBC : chronic, progressive
More informationObeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks Evidence Report July 26, 2016 Institute for Clinical and Economic
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk PBC for Healthcare Practitioners Introduction
More informationAutoimmune and cholestatic liver diseases
Autoimmune and cholestatic liver diseases Prof. Tom Hemming Karlsen Research Institute of Internal Medicine & Department of Transplantation Medicine University of Oslo & Oslo University Hospital, Norway
More informationHépatopathies auto-immunes
16 ème Journée d'automne Lausanne, le 19 octobre 2017 Hépatopathies auto-immunes Nurullah Aslan et Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationCurrent Concepts in the Management and Treatment of PBC & PSC
Current Concepts in the Management and Treatment of PBC & PSC Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London A family affair? Central vein Hepatocytes
More informationSubject: Obeticholic Acid (Ocaliva ) Tablet
09-J2000-65 Original Effective Date: 09/15/16 Reviewed: 07/11/18 Revised: 08/15/18 Subject: Obeticholic Acid (Ocaliva ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationPRIMARY BILIARY CHOLANGITIS: DIAGNOSIS AND MANAGEMENT Project ID:
ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint
More informationImproving the Lives of Patients with Liver Diseases
Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and
More informationNoncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis
Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids Cholestasis Biochemical hallmark Impaired bile flow from liver to small intestine Alkaline phosphatase is primary
More informationTABLE OF CONTENTS SYMPOSIUM AGENDA. Diagnosis, Stratification of Risk, and Initial Treatment in PBC
PBC Novel Pathways for Treatment of Cholestatic Liver Disease TABLE OF CONTENTS Faculty Biographies SYMPOSIUM AGENDA Introduction Kris V. Kowdley, MD Diagnosis, Stratification of Risk, and Initial Treatment
More informationAESOP Overview and Inclusion/Exclusion Criteria Richard Pencek, PhD
747-207 AESOP Overview and Inclusion/ Criteria Richard Pencek, PhD Sr Director, Clinical Research, Intercept Pharmaceuticals, Inc. 2 PSC Forum 2 AESOP: A Phase 2 Randomized, Placebo-Controlled Trial, Dose-Finding
More informationShifting Paradigms in Primary Biliary Cholangitis A CE/CME Activity
Overview Shifting Paradigms in Primary Biliary Cholangitis A CE/CME Activity In this video series, Kris Kowdley, MD, and Seth Sclair, MD, share insight into changes in the management of patients with primary
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis What is primary biliary cholangitis? Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease. When a person has PBC, the immune
More informationPrimary biliary cholangitis
A guide to Primary biliary cholangitis Miss Jennifer Hayden, Autoimmune Liver Disease Clinical Nurse Specialist Professor Gideon M Hirschfield, Professor and Consultant Transplant Hepatologist Centre for
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationPrimary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study
LINDOR ET AL. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases Keith D. Lindor 1, Christopher L. Bowlus 2, James Boyer 3, Cynthia Levy 4,
More informationTowards Precision Medicine in Primary Biliary Cholangitis
Riunione Monotematica A.I.S.F. 2016 THE FUTURE OF LIVER DISEASES: Beyond HCV is there a role for the hepatologist? 14 th October 2016 Towards Precision Medicine in Primary Biliary Cholangitis Marco Carbone,
More informationACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationMorning Report Presentation. Sarah Hughes, MD January 11, 2005
Morning Report Presentation Sarah Hughes, MD January 11, 2005 Primary Biliary Cirrhosis! PBC is a chronic, progressive, cholestatic liver disease of unknown cause that usually affects middle-aged women
More informationLiver Disease That Presents with Jaundice (PBC, Alcohol and Drugs): Diagnosis and Patient Management. Emma Pham, PA-C
Liver Disease That Presents with Jaundice (PBC, Alcohol and Drugs): Diagnosis and Patient Management Emma Pham, PA-C Case: JL (jaundiced lady) A 72 year old woman presents to her primary care provider
More informationTREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)
TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC) URSO not indicated Therapy for PBC Difficulties Etiology is uncertain Therapies are based on ideas regarding pathogenesis Present medical therapies have a limited
More informationSingle Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785
Single Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785 Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment
More informationPediatric PSC A children s tale
Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;
More informationKa-Shing Cheung, MBBS, MPH 1, Wai-Kay Seto, MD 1,2, James Fung, MD 1,2, Ching-Lung Lai, MD 1,2 and Man-Fung Yuen, MD, PhD 1,2
Citation: (2017) 8, e100; doi:10.1038/ctg.2017.23 Official journal of the American College of Gastroenterology www.nature.com/ctg Prognostic Factors for Transplant-Free Survival and Validation of Prognostic
More informationEfficacy and Safety of Seladelpar in Primary Biliary Cholangitis 52-Week Analysis of a Dose-Ranging Phase 2 Study
Efficacy and Safety of Seladelpar in Primary Biliary Cholangitis 52-Week Analysis of a Dose-Ranging Phase 2 Study Bowlus CL, Neff G, Aspinall R, Galambos M, Goel A, Hirschfield G, Kremer AE, Mayo MJ, Swain
More informationPrimary biliary cholangitis (PBC), previously known as primary
Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis Runalia Bahar, MD, Kimberly A. Wong, MD, Chung H. Liu, and Christopher L. Bowlus, MD Dr Bahar is a hospitalist
More informationOverview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN
Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN 2012 Annual Conference PSC Partners Seeking a Cure May 5, 2012 Primary Sclerosing Cholangitis Multifocal
More informationI have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES
LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate
More informationPrimary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants
Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic
More informationManagement of cholestatic diseases Today and tomorrow
12th Paris Hepatology Conference Management of cholestatic diseases Today and tomorrow Paris 15 January 2019 U. Beuers Department of Gastroenterology & Hepatology Tytgat Institute for Liver and Intestinal
More informationOCALIVA (obeticholic acid) oral tablet
OCALIVA (obeticholic acid) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationHangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam
Clinical Aspects of Primary Biliary Cirrhosis Hangzhou, 15 March 2008 Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Epidemiology of Primary
More informationSarah Landes October 23, 2014
Sarah Landes October 23, 2014 A T-cell mediated inflammatory destruction of intralobular bile ducts progressively leading to cholestasis and cirrhosis 9:1 F to M ratio Mostly diagnosed between 30-60 years
More informationKey Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto
Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationPrimary biliary cirrhosis (PBC) is an autoimmune
Early Biochemical Response to Ursodeoxycholic Acid and Long-Term Prognosis of Primary Biliary Cirrhosis: Results of a 14-Year Cohort Study Li-Na Zhang, 1,2 * Tian-Yan Shi, 1,2 * Xu-Hua Shi, 1,2 Li Wang,
More informationHEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM
EVALUATION OF LIVER FUNCTION R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM METABOLIC FUNCTION
More informationHepatic Transporter Proteins involved in Bile Formation
Bile salt synthesis Hepatic Transporter Proteins involved in Bile Formation Basolateral membrane transporter proteins fx: NTCP uptake of bile salts OATP bulky organic anions Canalicular membrane transporter
More informationPrimary biliary cholangitis (PBC)
The PBC Network Primary biliary cholangitis (PBC) Living with your diagnosis Officially endorsed and reviewed by About this guide The European Association for the Study of the Liver (EASL) is a major European
More informationChronic Cholestatic Liver Diseases
Chronic Cholestatic Liver Diseases - EASL Clinical Practice Guidelines - Rome, 8 October 2010 Ulrich Beuers Department of Gastroenterology and Hepatology Tytgat Institute of Liver and Intestinal Research
More informationA Review of Liver Function Tests. James Gray Gastroenterology Vancouver
A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationPrimary Sclerosing Cholangitis Medical Management
Primary Sclerosing Cholangitis Medical Management Kapil Chopra M.D. Assistant Professor of Medicine Division of Transplant Medicine Mayo Clinic Arizona PSC Primary sclerosing cholangitis is a progressive
More informationPBC features and management in the era of UDCA and Budesonide
PBC features and management in the era of UDCA and Budesonide Raoul Poupon, MD Université P&M Curie, AP-Hôpitaux de Paris, Inserm, Paris, France The changing pattern of PBC Over the last 2 decades: More
More informationHow the concept of biochemical response influenced the management of primary biliary cholangitis over time
ORIGINAL ARTICLE How the concept of biochemical response influenced the management of primary biliary cholangitis over time W.J. Lammers 1 *, M. Leeman 1, C.I.J. Ponsioen 2, K. Boonstra 2, K.J. van Erpecum
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationTHE BRITISH SOCIETY OF GASTROENTEROLOGY/UK-PBC PRIMARY BILIARY CHOLANGITIS TREATMENT AND MANAGEMENT GUIDELINES
THE BRITISH SOCIETY OF GASTROENTEROLOGY/UK-PBC PRIMARY BILIARY CHOLANGITIS TREATMENT AND MANAGEMENT GUIDELINES AUTHORS: HIRSCHFIELD GM, DYSON JK, ALEXANDER GJ, CHAPMAN M, COLLIER J, HUBSCHER S, PATANWALA
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationIn primary biliary cholangitis (PBC), progression
HEPATOLOGY COMMUNICATIONS, VOL. 2, NO. 6, 2018 Clinical Application of the GLOBE and United Kingdom-Primary Biliary Cholangitis Risk Scores in a Trial Cohort of Patients With Primary Biliary Cholangitis
More informationCholestatic Liver Diseases: Update on Diagnosis and Management. Cholestatic Liver Diseases: Location of Injury Determines Phenotype
Cholestatic Liver Diseases: Update on Diagnosis and Management R. Todd Stravitz, M.D. Hume-Lee Transplant Center Section of Hepatology Virginia Commonwealth University Cholestatic Liver Diseases: Location
More informationMY DISCUSSION GUIDE. Personalize your treatment plan for primary biliary cholangitis (PBC).
I am not on OCALIVA (obeticholic acid) MY DISCUSSION GUIDE Personalize your treatment plan for primary biliary cholangitis (PBC). This guide is not intended to replace the advice of your healthcare team.
More informationNoninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD
Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis
More informationA Case of Autoimmune Hepatitis with Antimitochondrial Antibody and No Detectable Antinuclear Antibody
FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF St. Marianna Med. J. Case Report Vol. 32, pp. 33 38, 2004 FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF A Case
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More informationPatologia sistematica V Gastroenterologia Prof. Stefano Fiorucci Autoimmune liver diseases
Patologia sistematica V Gastroenterologia Prof. Stefano Fiorucci Autoimmune liver diseases Harrison s Principles of Internal Medicine 18-19 Ed. 2012 e seguenti Chronic hepatitis classification by cause
More informationNot All Patients With Liver Disease Have HCV Diagnosis and Management of Some Common Non HCV Liver Diseases
Not All Patients With Liver Disease Have HCV Diagnosis and Management of Some Common Non HCV Liver Diseases Prevalence of Chronic Liver Disorders in the United States Nonalcoholic Fatty Liver Disorder
More informationChronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths
Chronic Biliary Disease Dr Susan Davies & Dr Bill Griffiths Chronic Biliary Disease Terminology is confusing with pathologists and hepatologists using the same language BUT with different meanings. Chronic
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Original Article A -Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis F. Nevens, P. Andreone, G. Mazzella, S.I. Strasser, C. Bowlus, P. Invernizzi, J.P.H. Drenth, P.J. Pockros, J. Regula,
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationPrimary biliary cholangitis, previously called
Hepatology Communications, VOL. 0, NO.0, 2018 NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Marlyn J. Mayo, 1 Alan
More informationSeladelpar Interim Data Phase 2 Low Dose Study in PBC. July 17, 2017
Seladelpar Interim Data Phase 2 Low Dose Study in PBC July 17, 2017 Seladelpar Phase 2 Low Dose Study in PBC Potential for superior efficacy and better tolerability 39% (5 mg) and 45% (10 mg) reductions
More informationPBC and PSC: Back to Basics
Disclosure No financial interest or other relationship with the manufacturer(s) of the product(s) or provider(s) of the service(s) that will be discussed in this presentation. PBC and PSC: Back to Basics
More informationPutting NICE guidance into practice. Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443)
Putting NICE guidance into practice Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443) Published: April 2017 Summary Obeticholic acid is recommended as an option
More informationInterpreting Liver Function Tests
PSH Clinical Guidelines Statement 2017 Interpreting Liver Function Tests Dr. Asad A Chaudhry Consultant Hepatologist, Chaudhry Hospital, Gujranwala, Pakistan. Liver function tests (LFTs) generally refer
More informationInvestigating and Referring Incidental Findings of Abnormal Liver Tests
Investigating and Referring Incidental Findings of Abnormal Liver Tests Note on Referral Guidelines: these revised guidelines are presented as a tool to aid appropriate referral and management of common
More informationPrimary Biliary Cholangitis in Motion Meeting
Primary Biliary Cholangitis in Motion Meeting The PBC in Motion meeting took place on 10 th March 2018 in Heathrow, UK Chair People: Dave Jones, 1 Luigi Muratori 2 Speakers: Achim Kautz, 3 Gideon Hirschfield,
More informationACG Clinical Guideline: Primary Sclerosing Cholangitis
ACG Clinical Guideline: Primary Sclerosing Cholangitis Keith D. Lindor, MD, FACG 1, Kris V. Kowdley, MD, FACG 2, and M. Edwyn Harrison, MD 3 1 College of Health Solutions, Arizona State University, Phoenix,
More informationTitle: stratification and treatment of primary biliary cholangitis. Authors: Javier Martínez, Lara Aguilera, Agustín Albillos
Title: Risk stratification and treatment of primary biliary cholangitis Authors: Javier Martínez, Lara Aguilera, Agustín Albillos DOI: 10.17235/reed.2018.5662/2018 Link: PubMed (Epub ahead of print) Please
More informationHwajeong Lee, MD, Robert T. Stapp, DO, Adrian H. Ormsby, MD, and Veena V. Shah, MD
Anatomic Pathology / Overlap Syndrome The Usefulness of IgG and IgM Immunostaining of Periportal Inflammatory Cells (Plasma Cells and Lymphocytes) for the Distinction of Autoimmune Hepatitis and Primary
More informationSerologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I
Autoimmune Hepatitis By Thomas Frazier Objective What we need to know about AIH Diagnosis Treatment Difficulties in both Liver transplantation concerns AASLD Guidelines: Hepatology. 2010 Jun;51(6):2193-213.
More informationDhanpat Jain Yale University School of Medicine, New Haven, CT
Dhanpat Jain Yale University School of Medicine, New Haven, CT Case history 15 years old female presented with fatigue. Found to have features suggestive of cirrhosis with esophageal varices, splenomegaly
More informationMY DISCUSSION GUIDE. Get the most out of your OCALIVA treatment.
PBC I am currently taking OCALIVA (obeticholic acid) MY DISCUSSION GUIDE Get the most out of your OCALIVA treatment. This guide is not intended to replace the advice of your healthcare team. All decisions
More informationTHBA Platform - Bile acid imbalance
- Bile acid imbalance Bile acids play an important role in maintaining human health by means of signaling molecules in the regulation of bile formation, liver function and metabolism. The detergent effect
More informationUpdate on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics
More informationGEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE
GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE Kalliopi Azariadis 1, Nikolaos K. Gatselis 1, Kalliopi Zachou 1, Vasiliki Lygoura 1, Pinelopi Arvaniti 1, Eirini I. Rigopoulou 1, Georgia
More informationLa valutazione non invasiva delle Epatopatie Biliari Autoimmuni
La valutazione non invasiva delle Epatopatie Biliari Autoimmuni Marco Carbone, MD, PhD Divisione di Gastroenterologia Università di Milano Bicocca Milano UOC Gastroenterologia Ospedale Universitario San
More informationPrimary Biliary Cirrhosis
Primary Biliary Cirrhosis What is Primary Biliary Cirrhosis? Primary biliary cirrhosis (PBC) is a chronic liver disease resulting from progressive destruction of the bile ducts in the liver called the
More informationDiagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful?
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:935 940 Diagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful? REGAN L. EBBESON* and RICHARD
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More informationBiochemical Investigations in Liver Disease. Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya
Biochemical Investigations in Liver Disease Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya Biochemical markers Albumin ALP ALT, AST Gamma-glutamyl transpeptidase
More informationIdiopathic adulthood ductopenia manifesting as jaundice in a young male
Idiopathic adulthood ductopenia manifesting as jaundice in a young male Deepak Jain*,1, H. K. Aggarwal 1, Avinash Rao 1, Shaveta Dahiya 1, Promil Jain 2 1 Department of Medicine, Pt. B.D. Sharma University
More informationA Rational Evidence-based Approach to Abnormal Liver Tests
A Rational Evidence-based Approach to Abnormal Liver Tests Jane D. Ricaforte-Campos, MD FPCP, FPSG, FPSDE 2013 HSP Post-graduate Course Radisson Blu Hotel, Cebu City misnomer Liver Function Tests Does
More informationFatty Liver Disease A growing epidemic
Fatty Liver Disease A growing epidemic Updates in GIM for Primary Care Don C. Rockey March 9 th, 2018 Disclosures 2018 Research Funding (all to MUSC) NIH/NIDDK Actelion Pharmaceuticals Gilead Sciences
More informationThe Liver for the Nonhepatologist
The Liver for the Nonhepatologist Michael R. Charlton, MBBS, FRCP Hepatology Director and Medical Director of Liver Transplantation Intermountain Medical Center Salt Lake City, Utah FORMATTED: 05-14-15
More informationPrimary Biliary Cholangitis
PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk Primary Biliary Cholangitis info@pbcfoundation.org.uk www.pbcfoundation.org.uk
More informationApproach to the cholestatic patient
Approach to the cholestatic patient Tom Hemming Karlsen Oslo University Hospital, Norway ASSA SAGES, August 8th, 2015 Best of EASL is a program supported by an unrestricted medical education grant by Merck
More informationFat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationOverview of PSC Making the Diagnosis
Overview of PSC Making the Diagnosis Tamar Taddei, MD Assistant Professor of Medicine Yale University School of Medicine Overview Definition Epidemiology Diagnosis Modes of presentation Associated diseases
More informationPrognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score
pissn 2287-2728 eissn 2287-285X Original Article Clinical and Molecular Hepatology 2012;18:375-382 Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune
More informationPresentation and mortality of primary biliary cirrhosis in older patients
Age and Ageing 2000; 29: 305 309 Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET
More informationWELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here.
WELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here. Photograph of an actual patient What is OCALIVA? OCALIVA is a prescription medicine used to
More information